Global pharmaceutical company Eli Lilly (NYSE: LLY) will be reporting earnings this Thursday before market hours. Here’s what you need to know.

Eli Lilly beat analysts’ revenue expectations last quarter, reporting revenues of $22.97 billion, up 47.7% year on year. It was an exceptional quarter for the company, with a beat of analysts’ EPS estimates and an impressive beat of analysts’ full-year EPS guidance estimates.

Is Eli Lilly a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, the market is expecting Eli Lilly’s revenue to grow 28.4% year on year, slowing from the 53.9% increase it recorded in the same quarter last year.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business will stay the course heading into earnings. Eli Lilly has missed Wall Street’s revenue estimates multiple times over the last two years.

With Eli Lilly being the first among its peers to report earnings this season, we don’t have anywhere else to look to get a hint at how this quarter will unfold for pharmaceuticals stocks. However, there has been positive investor sentiment in the segment, with share prices up 3.6% on average over the last month. Eli Lilly is up 8.3% during the same time .

ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.

Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.